EMA Authorised: Winrevair — Merck Sharp & Dohme B.V.

View source ↗

Summary

Winrevair has been authorised by EMA, with therapeutic area listed as Hypertension and Pulmonary; orphan medicine designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension
• Pulmonary Arterial Hypertension

Drugs mentioned

• WINREVAIR (SOTATERCEPT-CSRK)

Snippet

Status: Authorised. Therapeutic area: Hypertension, Pulmonary. MAH: Merck Sharp & Dohme B.V.. Decision date: 07/05/2026. Orphan medicine